A number of clinical results have shown that the majority of human cancers are intractable ones that cannot be cured by standard therapies or the latest immunotherapies (such as immune checkpoint inhibitors and gene-modified T-cell therapies), and this has become an important issue in the field of modern oncology worldwide. We are taking on the challenge of overcoming intractable cancers with our nano-immunotherapy “T-ignite®” technology, which combines our proprietary state-of-the-art nanotechnology and cancer immunotherapy. We are also developing the following products or therapeutic technologies in collaboration with universities, AMED, and pharmaceutical companies in Japan and overseas.